(erythromycin 3%-benzoyl peroxide 5% topical gel)
For Dermatological Use Only – Not for Ophthalmic Use
Benzamycin® Pak contains erythromycin [(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3-C-
xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione]. Erythromycin is a macrolide antibiotic produced from a strain of Saccharopolyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids.
Benzamycin ® Pak is indicated for the topical treatment of acne vulgaris.
Media Articles Related to Benzamycin (Erythromycin / Benzoyl Peroxide Topical)
Laser for tattoo removal appears to improve facial acne scarring
Source: Dermatology News From Medical News Today [2014.11.25]
A laser used to remove unwanted tattoos appears to improve facial acne scarring, according to a study published online by JAMA Dermatology.
Laser Used to Remove Tattoos May Help Reduce Acne Scars
Source: MedicineNet Acne Specialty [2014.11.20]
Title: Laser Used to Remove Tattoos May Help Reduce Acne Scars
Category: Health News
Created: 11/20/2014 12:00:00 AM
Last Editorial Review: 11/20/2014 12:00:00 AM
Source: MedicineNet Boils Specialty [2014.10.17]
Title: Acne (Pimples)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/17/2014 12:00:00 AM
Acne Pictures Slideshow: A Visual Dictionary
Source: MedicineNet Acne Specialty [2014.10.16]
Title: Acne Pictures Slideshow: A Visual Dictionary
Created: 10/16/2014 12:00:00 AM
Last Editorial Review: 10/16/2014 12:00:00 AM
Health Tip: Help Prevent Acne Scars
Source: MedicineNet Acne Specialty [2014.10.01]
Title: Health Tip: Help Prevent Acne Scars
Category: Health News
Created: 10/1/2014 12:00:00 AM
Last Editorial Review: 10/1/2014 12:00:00 AM
Clinical Trials Related to Benzamycin (Erythromycin / Benzoyl Peroxide Topical)
Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.